within Pharmacolibrary.Drugs.ATC.L;

model L01FF10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.24 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Retifanlimab is a humanized monoclonal antibody that targets programmed death receptor-1 (PD-1), thereby modulating immune responses. It is developed for the treatment of various cancers, including metastatic squamous carcinoma. The drug is not yet widely approved but has been granted accelerated approval for certain indications such as Merkel cell carcinoma.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult cancer patients based on available monoclonal antibody pharmacokinetic data. No published population pharmacokinetic (PK) model or direct PK parameters for retifanlimab were identified in the literature.</p><h4>References</h4><ol><li><p>Rao, S, et al., &amp; Spano, JP (2022). POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. <i>Frontiers in oncology</i> 12 935383â€“None. DOI:<a href=&quot;https://doi.org/10.3389/fonc.2022.935383&quot;>10.3389/fonc.2022.935383</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36091159/&quot;>https://pubmed.ncbi.nlm.nih.gov/36091159</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FF10;
